Le Lézard
Classified in: Health, Science and technology
Subject: TDS

Intec Pharma to Participate in the Oppenheimer Specialty Pharma Summit



JERUSALEM, October 6, 2017 /PRNewswire/ --

Intec Pharma Ltd. (NASDAQ and TASE: NTEC) today announced that management will participate in the Oppenheimer Specialty Pharma Summit to be held October 11, 2017 at the Sofitel Hotel in New York City.

Date:  Wednesday, October 11, 2017

Venue: Sofitel New York Hotel

Format:  One-on-One Meetings with Investors

Presenter: Jeffrey A. Meckler, Chief Executive Officer of Intec Pharma

The investor presentation will be posted to the Events section of the Company's website at http://www.intecpharma.com.  

About Intec Pharma Ltd. 

Intec Pharma is a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology. The Company's Accordion Pill is an oral drug delivery system that is designed to improve the efficacy and safety of existing drugs and drugs in development by utilizing an efficient gastric retention and specific release mechanism. The Company's product pipeline includes two product candidates in clinical trial stages: Accordion Pill Carbidopa/Levodopa, or AP-CD/LD, which is being developed for the treatment of Parkinson's disease symptoms in advanced Parkinson's disease patients, and AP-CBD/THC, an Accordion Pill with the two primary cannabinoids contained in Cannabis sativa, cannabidiol (CBD) and tetrahydrocannabinol (THC), which is being developed for various indications including low back neuropathic pain and fibromyalgia.

Contacts:
Jeffrey A. Meckler
Chief Executive Officer
Intec Pharma Ltd.
+1-646-374-8050
jeffrey@intecpharma.com  

SOURCE Intec Pharma Ltd.


These press releases may also interest you

at 01:00
Royal DSM, a global science-based company, today presents its strategy update entitled "Growth & Value - Purpose led, Performance driven." at its Capital Markets Day in London (UK).      (Logo: https://mma.prnewswire.com/media/657851/DSM_Logo.jpg )...

at 01:00
LOS ANGELES, June 20, 2018 /PRNewswire-PRWeb/ -- Ovation Fertilitytm is proud to announce a partnership with the Institute for Reproductive Health in Cincinnati, OH, in which the Institute for Reproductive Health will merge its laboratory with...

19 jun 2018
Eidos Therapeutics, Inc. , a clinical stage biopharmaceutical company focused on addressing the large and growing unmet need in diseases caused by transthyretin (TTR) amyloidosis (ATTR), today announced the pricing of its initial public offering of...

19 jun 2018
The Honourable Ginette Petitpas Taylor, Minister of Health, the Honourable Jody Wilson-Raybould, Minister of Justice and Attorney General of Canada, along with Parliamentary Secretary Bill Blair, will be available to media to comment on the passage...

19 jun 2018
Galmed Pharmaceuticals Ltd. ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramcholtm, a once-daily, oral therapy for the treatment of nonalcoholic...

19 jun 2018
Emerald Health Therapeutics, Inc. (Emerald) today applauds the Canadian government's historic passing of Bill C-45 (Cannabis Act) to end Canada's near century-long prohibition of recreational cannabis and usher in a new era of cannabis regulation....




News published on 6 october 2017 at 07:00 and distributed by: